Results 61 to 70 of about 75,315 (267)

Case study: Acute plasmoblastic leukemia presentation following effective haploidentical hematopoietic stem cell transplantation therapy

open access: yesJournal of International Medical Research
Plasma cell leukemia is a rare and aggressive malignancy characterized by monoclonal gammopathy and the presence of circulating plasma cells in the peripheral blood.
Azat Karabekov   +7 more
doaj   +1 more source

Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively analyzed 475 transplant‐eligible patients who completed standard intensity treatment with or without HDM ...
Maximilian J. Steinhardt   +23 more
wiley   +1 more source

Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma

open access: yesJournal of International Medical Research
Objective Follicular lymphoma (FL) is an indolent, lymphoproliferative disease of B-cell origin that has a heterogeneous disease course with varying outcomes. Certain patients may undergo autologous stem cell transplantation.
Anna Kenyeres   +4 more
doaj   +1 more source

Amniotic fluid stem cells for minimally invasive prenatal cell therapy

open access: yesGynecology and Minimally Invasive Therapy, 2014
Amniotic fluid stem cells can be expanded without feeder layers and can differentiate into mesenchymal and hematopoietic lineages. Long-term engraftment has been difficult to achieve after prenatal stem cell transplantation, mainly because of allogeneic ...
Sheng-Wen Steven Shaw
doaj   +1 more source

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Exagamglogene autotemcel (exa‐cel) is a one‐time, ex vivo, CRISPR‐Cas9 gene edited cell therapy approved for patients with transfusion dependent β‐thalassemia (TDT) aged 12–35 years. In a Phase 3 study (CLIMB THAL‐111), exa‐cel treatment resulted in reactivation of fetal hemoglobin and increases in total hemoglobin, leading to transfusion ...
Sujit Sheth   +25 more
wiley   +1 more source

The future of autologous stem cell transplantation in myeloma

open access: yesBlood, 2014
Abstract Autologous stem cell transplantation (ASCT) has long been considered frontline therapy for newly diagnosed myeloma patients. This Spotlight examines the role of ASCT in the era of novel drugs and argues that ASCT should continue to be considered for eligible patients.
Frits van Rhee   +2 more
openaire   +3 more sources

Autologous hematopoietic stem cell transplantation as first‐line consolidation therapy can improve the prognosis of diffuse large B‐cell lymphoma with high expression of MYC protein

open access: yesKaohsiung Journal of Medical Sciences, 2019
Myc‐positive diffuse large B‐cell lymphoma has lower curative efficacy and long‐term survival than its negative counterpart, even when treated with R‐CHOP regimen.
Kai Hu   +7 more
doaj   +1 more source

Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation

open access: yesCell Reports, 2019
Summary: Clonal hematopoiesis of indeterminate potential (CHIP) is caused by recurrent somatic mutations leading to clonal blood cell expansion. However, direct evidence of the fitness of CHIP-mutated human hematopoietic stem cells (HSCs) in blood ...
Christina A. Ortmann   +20 more
doaj   +1 more source

Hematopoietic stem cell transplantation for the management of follicular lymphoma

open access: yesStem Cells and Cloning: Advances and Applications, 2010
Chitra HosingDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USAAbstract: Although much has been published on the application of autologous and allogeneic hematopoietic ...
Chitra Hosing
doaj  

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network (EMN)

open access: yesAmerican Journal of Hematology, EarlyView.
Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Heinz Ludwig   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy